Cognizant and Boehringer Ingelheim have launched an end-to-end technology platform powered by the Veeva Development Cloud, designed to accelerate Boehringer Ingelheim’s delivery of life-transforming treatments. The milestone marks the completion of Phase One of the collaboration, which was first announced in 2023.

Boehringer’s “One Medicine Platform” replaces over 20 legacy platforms—unifying medicinal development processes and data sources into a connected ecosystem in order to enhance cross-functionality and operational efficiencies.

With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.

“For years, Boehringer Ingelheim used multiple vendor systems which lacked the ability to communicate with each other, which led to complex workflows. The launch of our One Medicine Platform revolutionizes our medicinal development processes and takes our operational efficiencies to the next level,” said Oliver Fink, Head Learning, Processes & Digitalization, Global Quality Medicine at Boehringer Ingelheim.

“We are pleased to achieve this program milestone in our collaboration with Boehringer Ingelheim,” said Gagan Syal, Head of Life Sciences, EMEA & APAC, at Cognizant. “With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams, we have been able to execute this project in record-time.”